Alto Neuroscience and Fractyl Health add to biotech IPO momentum in Friday doubleheader
Two more biotechs will go public Friday morning as Alto Neuroscience and Fractyl Health build on the momentum created by CG Oncology and ArriVent BioPharma’s Nasdaq listings last week.
California drugmaker Alto Neuroscience raised about $128.6 million in its upsized NYSE listing, as the mid-stage CNS biotech priced at $16 apiece $ANRO, the high end of the range it proposed earlier this week. Fractyl Health, meanwhile, landed on the Nasdaq with $110 million in proceeds by pricing at $15 a share $GUTS, the mid-point of the range it disclosed on Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.